Trial: 201902012

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)


III (Cancer Control)

Principal Investigator

Badiyan, Shahed

Disease Site

Lung; Lung Cancer – Non-small Cell

Learn more about this study at: